All In Biotech

Drug Trial Radar · NCT05551221

The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia

The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia (BPH) Complicated With Lower Urinary Tract Symptoms (LUTS) -A Multicenter, Prospective, Randomized, Investigator-blind, Active Controlled Study

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Sep 21, 2022

Primary completion

Sep 10, 2024

Study completion Sep 10, 2024

Sponsor

Lead sponsor
Xintian PharmaceuticalIndustry
Sponsor type
Industry
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 60 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective: To evaluate the efficacy and safety of Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules. Study design: A multicenter, prospective, randomized, investigator-blind, active controlled clinical study. Interventions: Group A: Oral Tamsulosin Hydrochloride Capsules for 12 weeks. Group B: Oral l Silodosin Capsules for 12 weeks.

Conditions

  • Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

Interventions

  • Silodosin CapsulesDrug

    Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule,1 capsule/time, bid, after breakfast and dinner.

  • TamsulosinDrug

    Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. International Prostate Symptom Score(IPSS)Time frame: 12 week

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • The Central Hospital Of WUHAN

    Wuhan, Hubei, China

  • Wuhan No.1 Hospital

    Wuhan, Hubei, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Wuxi No.2 People's Hospital

    Wuxi, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.